Bariatric surgery as a long-term treatment for type 2 diabetes/metabolic syndrome

• Main Authors: Nor Hanipah, Zubaidah, Schauer, Philip R.
• Format: Article
• Language: English
• Published: Annual Reviews 2020
• Online Access: http://psasir.upm.edu.my/id/eprint/88008/1/ABSTRACT.pdf; http://psasir.upm.edu.my/id/eprint/88008/; https://www.annualreviews.org/doi/10.1146/annurev-med-053117-123246?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
• Institution: Universiti Putra Malaysia

Metabolic surgery is increasingly becoming recognized as a more effective treatment for patients with type 2 diabetes (T2D) and obesity as compared to lifestyle modification and medical management alone. Both observational studies and clinical trials have shown metabolic surgery to result in sustained weight loss (20-30%), T2D remission rates ranging from 23% to 60%, and improvement in cardiovascular risk factors such as hypertension and dyslipidemia. Metabolic surgery is cost-effective and relatively safe, with perioperative risks and mortality comparable to low-risk procedures such as cholecystectomy, hysterectomy, and appendectomy. International diabetes and medical organizations have endorsed metabolic surgery as a standard treatment for T2D with obesity.